Treatment of Alzheimer's disease in the long-term-care setting

American Journal of Health-System Pharmacy

Volumn 66, Issue 10, 2009, Pages 899-907

  Smith, David A ^a,b  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b Geriatric Consultants of Central Texas   (United States)

Author keywords

Alzheimer disease; Central nervous system drugs; Donepezil; Galantamine; Long term care facilities; Mechanism of action; Memantine; Parasympathomimetic agents; Rivastigmine; Toxicity

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEALTH CARE COST; HEALTH CARE FACILITY; HUMAN; LONG TERM CARE; MINI MENTAL STATE EXAMINATION; NURSING HOME; NURSING HOME PATIENT; PRIORITY JOURNAL; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 65649137775     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070622     Document Type: Article

References (59)

1. Hebert LE, Scherr PA, Bienias JL et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003; 60:1119-1122 (Pubitemid 36975801)
2. Evans DA, Funkenstein HH, Albert MS et al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. JAMA. 1989; 262:2551-2556 (Pubitemid 19264973)
3. Galasko D. An integrated approach to the management of Alzheimer's disease: assessing cognition, function and behavior. Eur J Neurol. 1998; 5(suppl 4):S9-S17. (Pubitemid 28550113)
4. Helmer C, Pérès K, Letenneur L et al. Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity. Dement Geriatr Cogn Disord. 2006; 22:87-94. (Pubitemid 43909834)
5. Tariot PN, Cummings JL, Katz IR et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc. 2001; 49:1590-1599 (Pubitemid 34007984)
6. Winblad B, Kilander L, Eriksson S et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet. 2006; 367:1057-65. [Erratum, Lancet. 2006; 367:1980.] [Erratum, Lancet. 2006; 368:1650.]
7. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999; 14:135-146 (Pubitemid 29110331)
8. Cummings JL, Koumaras B, Chen M et al. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study Am J Geriatr Pharmacother. 2005; 3:137-148 (Pubitemid 41644452)
9. Aupperle PM, Koumaras B, Chen M et al. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study. Curr Med Res Opin. 2004; 20:1605-1612 (Pubitemid 39457548)
10. Qaseem A, Snow V, Cross JT Jr et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008; 148:370-378
11. McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34:939-944 (Pubitemid 14076461)
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994:142, 684.
13. Singer C, Luxenberg J. Diagnosing dementia in long-term care facilities. J Am Med Dir Assoc. 2003; 4(suppl 6): S134-S140. (Pubitemid 37527481)
14. Small GW, Rabins PV, Barry PP et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997; 278:1363-1371 (Pubitemid 27449698)
15. American Medical Directors Association. Dementia: clinical practice guideline 1998. Columbia, MD: American Medical Directors Association; 1998.
16. Nygaard HA, Ruths S. Missing the diagnosis: senile dementia in patients admitted to nursing homes. Scand J Prim Health Care. 2003; 21:148-152 (Pubitemid 37174003)
17. Macdonald AJ, Carpenter GI. The recognition of dementia in "non-EMI" nursing home residents in South East England. Int J Geriatr Psychiatry. 2003; 18:105-108
18. Barton C, Miller B, Yaffe K. Improved evaluation and management of cognitive impairment: results of a comprehensive intervention in long-term care. J Am Med Dir Assoc. 2006; 7:84-89 (Pubitemid 43224466)
19. Hartmaier SL, Sloane PD, Guess HA et al. Validation of the Minimum Data Set Cognitive Performance Scale: agreement with the Mini-Mental State Examination. J Gerontol Biol Sci Med Sci. 1995; 50:M128-33.
20. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001; 57:489-95. (Pubitemid 32757598)
21. Holmes C, Wilkinson D, Dean C et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology. 2004; 63:214-219 (Pubitemid 38971117)
22. Tariot PN, Solomon PR, Morris JC et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 2000; 54:2269-2276
23. Rosler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999;318:633-638 (Pubitemid 29192055)
24. Peskind ER, Potkin SG, Pomara N et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006; 14:704-715 (Pubitemid 44196270)
25. Shua-Haim JR, Smith JM, Patel SR et al. Galantamine delays nursing home transfers in Alzheimer's disease (AD) patients residing in assisted living facilities. Alzheimers Demen. 2006; 2:S636. Abstract.
26. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141:1356-1364
27. Galasko D, Bennett D, Sano M et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997; 11(2suppl):S33-9. (Pubitemid 27303108)
28. Schneider LS, Olin JT, Doody RS et al. Validity and reliability of the Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change. Alzheimer Dis Assoc Disord. 1997; 11(2 suppl):S22-32. (Pubitemid 27303107)
29. Morris JC. The Clinical Dementia Rating Scale (CDR): current version and scoring rules. Neurology. 1993; 43:2412-2414 (Pubitemid 23346995)
30. Guy W. Clinical global impressions. In: Guy W, ed. ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institutes of Health; 1976:217-220
31. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198
32. Cummings JL, Mega M, Gray K et al. The Neuropsychiatrie Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44:2308-2314 (Pubitemid 24382728)
33. Wood S, Cummings JL, Hsu MA et al. The use of the neuropsychiatric inventory in nursing home residents: characterization and measurement. Am J Geriatr Psychiatry. 2000; 8:75-83. (Pubitemid 30036844)
34. Schmitt FA, Ashford W, Ernesto C et al. The Severe Impairment Battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997; 11(2 suppl):S51-6. (Pubitemid 27303110)
35. Winblad B, Wimo A, Engedal K et al. 3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy. Dement Geriatr Cogn Disord. 2006; 21:353-363 (Pubitemid 43735680)
36. Reisberg B, Doody R, Stöffler A et al. A 24-week open-label extension study of memantine in moderate-to-severe Alzheimer disease. Arch Neurol. 2006; 63:49-54. (Pubitemid 43063861)
37. Farlow M, Anand R, Messina J Jr et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol. 2000; 44:238-241 (Pubitemid 32260563)
38. Lyketsos CG, Reichman WE, Kershaw P et al. Long-term outcomes of galantamine treatment in patients with Alzheimer disease. Am J Geriatr Psychiatry. 2004; 12:473-482 (Pubitemid 39181062)
39. Raina P, Santaguida P, Ismaila A et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008; 148:379-397
40. Doraiswamy PM, Kaiser L, Bieber F et al. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord. 2001; 15:174-183 (Pubitemid 33117033)
41. Mann JL, Evans TS, O'Hara LM. An assessment of the diagnosis and management of dementia in nursing homes. Consult Pharm. 2005; 20:306-312 (Pubitemid 41132138)
42. Dybicz SB, Keohane DJ, Erwin WG et al. Patterns of cholinesterase- inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother. 2006; 4:154-160 (Pubitemid 44057811)
43. Pedone C, Lapane KL, Mor V et al. Donepezil use in US nursing homes. Aging Clin Exp Res. 2004; 16:60-67
44. Aricept (donepezil hydrochloride) package insert. Woodcliff Lake, NJ: Eisai Inc.; 2006 Nov.
45. Razadyne (galantamine) package insert. Titusville, NJ: Ortho-McNeil Neurologics, Inc.; 2007 Apr.
46. Namenda (memantine hydrochloride) package insert. St Louis, MO: Forest Laboratories, Inc.; 2007 Apr.
47. Exelon (rivastigmine tartrate) package insert. East Hanover, NJ: Novartis; 2006 Jun.
48. Exelon (rivastigmine transdermal system) patch package insert. East Hanover, NJ: Novartis; 2007 Jul.
49. Lanctôt KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta- analysis. CMAJ. 2003; 169:557-564 (Pubitemid 37174596)
50. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials. BMJ. 2005; 331:321-327 (Pubitemid 41113141)
51. Burns A, O'Brien J, BAP Dementia Consensus group et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006; 20:732-755 (Pubitemid 44622739)
52. O'Brien JA, Caro JJ. Alzheimer's disease and other dementia in nursing homes: levels of management and cost. Int Psychogeriatr. 2001; 13:347-358 (Pubitemid 33101673)
53. Hill J, Fillit H, Thomas SK et al. Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias. Pharmacoeconomics. 2006; 24:265-280
54. Kleinman L, Schmier J, Rothman M et al. Time and costs of managing specific disruptive behaviors in long-term care facilities: a descriptive study. Consult Pharm. 2002; 17:497-507.
55. Reisberg B, Doody R, Stoffler A et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348:1333-1341 (Pubitemid 36951375)
56. Black SE, Doody RS, Li H et al. Donepezil preserves cognition and global function in severe Alzheimer's disease patients. Neurology. 2007; 69:459-469 (Pubitemid 47450281)
57. Feldman H, Gauthier S, Hecker J et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001; 57:613-620 (Pubitemid 32782987)
58. Monsch AU, Giannakopoulos P, GAL-SUI-1 Study Group. Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease. Curr Med Res Opin. 2004; 20:931-938 (Pubitemid 38821532)
59. Gauthier S, Juby A, Rehel B et al. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. Int J Clin Pract. 2007; 61: 886-895 (Pubitemid 46744076)